Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Receives Average Rating of “Moderate Buy” from Brokerages

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) has been assigned an average rating of “Moderate Buy” from the six ratings firms that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company.

A number of analysts have commented on BIOVF shares. BNP Paribas Exane upgraded shares of Swedish Orphan Biovitrum to an “outperform” rating in a report on Tuesday, February 10th. Zacks Research upgraded Swedish Orphan Biovitrum to a “hold” rating in a report on Thursday, May 7th. Barclays reiterated an “overweight” rating on shares of Swedish Orphan Biovitrum in a report on Tuesday, February 24th. HC Wainwright initiated coverage on Swedish Orphan Biovitrum in a report on Wednesday, May 6th. They set a “buy” rating on the stock. Finally, Danske lowered Swedish Orphan Biovitrum to a “hold” rating in a report on Thursday, February 19th.

Swedish Orphan Biovitrum Price Performance

BIOVF stock opened at $48.00 on Wednesday. The company has a market cap of $17.09 billion, a price-to-earnings ratio of 160.00 and a beta of 0.36. The company has a current ratio of 0.70, a quick ratio of 0.47 and a debt-to-equity ratio of 0.19. Swedish Orphan Biovitrum has a 12 month low of $27.06 and a 12 month high of $48.00. The firm has a 50-day moving average of $44.16 and a two-hundred day moving average of $39.61.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last released its quarterly earnings data on Tuesday, April 28th. The company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.07. The company had revenue of $755.76 million during the quarter, compared to the consensus estimate of $749.76 million. Swedish Orphan Biovitrum had a net margin of 3.37% and a return on equity of 16.66%. As a group, analysts forecast that Swedish Orphan Biovitrum will post 2.22 earnings per share for the current fiscal year.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.